Welcome to our dedicated page for SS Innovations International SEC filings (Ticker: SSII), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on SS Innovations International's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into SS Innovations International's regulatory disclosures and financial reporting.
What happened: SS Innovations reported strong sales growth this quarter and in the first half of 2025, driven by system and instrument sales. Total revenue for the quarter was $10.0M and for the first six months $15.1M. Gross profit rose and operating results improved to a small positive operating income for the quarter, and the company completed an uplisting to NASDAQ.
Why it matters: The company boosted cash to $17.6M after financings and conversions, which helps near-term operations, but it still reported a $5.94M net loss for the first half and a small quarterly net loss after tax. Management discloses substantial doubt about the company’s ability to continue as a going concern and notes dependence on related-party financing and convertible note conversions.
SS Innovations International, Inc. (Nasdaq: SSII) filed a Form 8-K dated 15 July 2025 to disclose an operational milestone. The company reports that it has now installed more than 100 SSi Mantra surgical robotic systems across India and six other countries. Collectively, the installed base has facilitated over 5,000 surgical procedures, including 240 cardiac surgeries and 32 telesurgeries.
The filing contains no revenue, earnings, guidance or transactional information; it simply furnishes the related press release as Exhibit 99.1. While financial details are absent, the figures provided highlight growing clinical adoption and an expanding geographic presence for the Mantra platform.
SS Innovations International, Inc. (SSII) filed an amended Form 4 for Director and COO-Americas Barry F. Cohen. The amendment corrects the total share count after three small open-market purchases:
- 100 shares at $8.75 on 04/17/2025
- 100 shares at $8.90 on 04/22/2025
- 226 shares at $9.00 on 04/22/2025
The transactions add 426 shares in total, bringing Cohen’s directly held position to 8,866,888 common shares. No derivative securities were involved. The filing states the prior Form 4 contained an inadvertent misstatement of holdings, which is now rectified. While the dollar value of the purchases is modest, insider buying—especially by a director/officer—can be interpreted as a signal of confidence. However, the tiny size relative to Cohen’s existing 8.87 million-share stake limits financial materiality.